Hip bursitis treatment means care for soreness outside your hip

Outer hip pain gets worse when the sore spot is pressed

Side sleeping puts steady weight on the sore cord. That's why bed may hurt before a walk does.

Crossed legs can add the same pressure during the day. Standing with one hip pushed outward can keep the spot pressed for a long time.

The name doesn't decide the care. A hands-on check helps sort out whether the outside cords, the joint, or the lower back is involved.

Less pressure and guided strength can help

Don't sleep on the sore side for now. Turn over and keep your knees apart with a pillow.

Flat ground and shorter steps are often easier than hills. A walk was too much if you limped or woke up more sore the next morning.

Strength work doesn't mean guessing at gym machines. Ask a doctor or physical therapist whether slow chair rises are a safe place for you to begin.

Build only when the move stays smooth and the next morning isn't worse. Stop and call for advice if soreness turns sharp or your leg feels weak.

Hip bursitis treatment begins with an exam of the sore spot

See the doctor when night soreness doesn't ease after changing position. Fever, weight loss, or feeling ill calls for care sooner.

A regular visit checks the tender point, hip motion, leg strength, and the way you walk. Ask whether an X-ray would help or only show changes that aren't causing this soreness.

For now, uncross the legs and keep both feet under you when standing. QC Kinetix's medical providers are licensed clinic staff offering non-surgical regenerative care; for PRP, or platelet-rich plasma, they spin a sample of your blood to concentrate platelets.

Sources

1. In a three-arm randomized trial of 204 people with MRI-confirmed gluteal tendinopathy, an eight-week physiotherapist-led education and exercise programme produced success on global rating of change in 51/66 participants at 8 weeks versus 38/65 for a single corticosteroid injection and 20/68 for wait-and-see. Education plus exercise beat the injection at 8 weeks (risk difference 19.9%) and still beat it at 52 weeks (20.4%).

   Mellor R, et al. — Education plus exercise versus corticosteroid injection use versus a wait and see approach on global outcome and pain from gluteal tendinopathy: prospective, single blinded, randomised clinical trial.. BMJ, 2018. DOI: 10.1136/bmj.k1662.

2. A 2025 systematic review restricted to medium/high-quality low-risk-of-bias RCTs found only four interventions with demonstrated efficacy in gluteal tendinopathy: exercise and education (moderate strength, medium short-term effect on pain SMD 0.95 and function SMD 0.91), corticosteroid injection (small short-term pain effect SMD 0.51), PRP (superior to corticosteroid for short-term function), and focused shockwave therapy (long-term pain superiority over corticosteroid). Exercise and education is the recommended core.

   Bremer T, et al. — The efficacy of gluteal tendinopathy treatments: A systematic review.. Clinical Rehabilitation, 2025. DOI: 10.1177/02692155251327298.

3. In a double-blind RCT of 80 patients with chronic gluteal tendinopathy, a single ultrasound-guided intratendinous PRP injection produced a significantly better modified Harris Hip Score at 12 weeks than a single corticosteroid injection (74.05 vs 67.13, P=.048), with 82% versus 56.7% reaching the minimal clinically important difference.

   Fitzpatrick J, et al. — The Effectiveness of Platelet-Rich Plasma Injections in Gluteal Tendinopathy: A Randomized, Double-Blind Controlled Trial Comparing a Single Platelet-Rich Plasma Injection With a Single Corticosteroid Injection.. American Journal of Sports Medicine, 2018. DOI: 10.1177/0363546517745525.

4. At two-year follow-up of the same 80-patient trial, the leukocyte-rich PRP group continued to improve (mHHS 53.77 at baseline to 82.59 at 104 weeks, P<.0001) while the corticosteroid group peaked at about 6 weeks and had lost the benefit by 24 weeks; 27 corticosteroid patients were deemed treatment failures at 16-24 weeks and crossed over.

   Fitzpatrick J, et al. — Leucocyte-Rich Platelet-Rich Plasma Treatment of Gluteus Medius and Minimus Tendinopathy: A Double-Blind Randomized Controlled Trial With 2-Year Follow-up.. American Journal of Sports Medicine, 2019. DOI: 10.1177/0363546519826969.

5. FDA states verbatim that regenerative medicine products including stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosomes have NOT been approved 'for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders affecting blood production.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA, 2026.

6. The AAOS evidence-based clinical practice guideline on Management of Osteoarthritis of the Hip states verbatim: STRONG evidence supports intra-articular corticosteroids to improve function and reduce pain in the SHORT TERM; STRONG evidence does NOT support intra-articular hyaluronic acid, because it does not perform better than placebo for function, stiffness and pain; STRONG evidence supports physical therapy for mild to moderate symptoms; STRONG evidence supports NSAIDs for short-term pain and function; and MODERATE evidence does not support glucosamine sulfate.

   American Academy of Orthopaedic Surgeons — Management of Osteoarthritis of the Hip: Evidence-Based Clinical Practice Guideline.. AAOS, 2017.